SCHEMBL25257958

SCHEMBL25257958

CC1(C(=O)O)CC2(COC2)C1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.46
MAPK1 P28482 3/20 0.37
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37
CYP2C19 P33261 1/20 0.37
THPO P40225 1/20 0.37
STAT6 P42226 1/20 0.37
HIF1A Q16665 1/20 0.37
NPC1 O15118 1/20 0.37
GMNN O75496 1/20 0.37
LMNA P02545 1/20 0.37
MTOR P42345 1/20 0.37
RAB9A P51151 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EPHX1 P07099 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25304930 0.82 ATM (0.36) FFAR3SMN1; SMN2
SCHEMBL353254 0.79
SCHEMBL16700713 0.77 FFAR3 (0.60) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL14012097 0.76 FFAR3 (0.65) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL503244 0.76 FFAR3 (0.65) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL405480 0.76 FFAR3 (0.65) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL13490845 0.76 FFAR3 (0.65) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL4442780 0.76 FFAR3 (0.65) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL11637985 0.73 FFAR3 (0.55) FFAR3MAPK1TP53NFKB1CYP2C19
SCHEMBL25299400 0.71 ATM (0.39) MAPK1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463442-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2024-11-20 EP disclosed
CN-118613473-A Compounds and compositions for treating disorders associated with STING activity 艾福姆德尤股份有限公司 2024-09-06 CN disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-08-10 US disclosed
WO-2023137034-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250060-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 FFAR3 3650/4885MAPK1 1593/4885TP53 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.